OS1.1 Plasma PD-L1 levels over time differ between glioblastoma and lower-grade glioma patients

BACKGROUND: Immune modulating therapies are a promising treatment approach in patients with primary brain tumors, however their clinical efficacy is still under investigation as the systemic inflammatory responses are potentially challenged by the brain’s tight immune regulatory mechanisms. Here, we...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Neuro Oncol
Autori principali: Mair, M, Ilhan-Mutlu, A, Pajenda, S, Widhalm, G, Dieckmann, K, Hainfellner, J A, Marosi, C, Wagner, L, Preusser, M, Berghoff, A S
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2019
Soggetti:
Oral Presentations
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6795000/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz126.014
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi